Mortality in chronic pulmonary aspergillosis: a systematic review and individual patient data meta-analysis
Abhinav Sengupta,Animesh Ray,Ashish Datt Upadhyay,Koichi Izumikawa,Masato Tashiro,Yuya Kimura,Felix Bongomin,Xin Su,Thomas Maitre,Jacques Cadranel,Vitor Falcao de Oliveira,Nousheen Iqbal,Muhammad Irfan,Yurdagül Uzunhan,Juan Aguilar-Company,Oxana Munteanu,Justin Beardsley,Koji Furuuchi,Takahiro Takazono,Akihiro Ito,Chris Kosmidis,David W Denning
DOI: https://doi.org/10.1016/s1473-3099(24)00567-x
IF: 71.421
2024-12-01
The Lancet Infectious Diseases
Abstract:Summary Background Despite antifungal treatment, chronic pulmonary aspergillosis (CPA) is associated with substantial morbidity and mortality. We conducted a systematic review and meta-analysis to evaluate rates of mortality and its predictors in CPA. Methods A systematic literature search was conducted across MEDLINE (PubMed), Scopus, Embase, and Web of Science to identify studies in English, reporting mortality in CPA, from database inception to Aug 15, 2023. We included clinical studies, observational studies, controlled trials, and abstracts. Case reports, animal studies, letters, news, and literature reviews were excluded. Authors of studies published since 2016 were also contacted to obtain anonymised individual patient data (IPD); for other studies, summary estimates were extracted. Subgroup analysis was done for differences in overall 1-year and 5-year mortality, data source, study design, risk of bias, country, Human Development Index, age groups, and the underlying lung disease. We used random-effects meta-analyses to estimate pooled mortality rates. Subgroup analyses and meta-regression were done to explore sources of heterogeneity. One-stage meta-analysis with a stratified Cox proportional hazards model was used to estimate the univariable and hazards for mortality, adjusting for age, sex, type of CPA, treatment, and underlying pulmonary comorbidities. This study was registered with PROSPERO (CRD42023453447). Findings We included 79 studies involving 8778 patients in the overall pooled analysis and 15 studies involving 1859 patients in the IPD meta-analysis. Pooled mortality (from 70 studies) was estimated at 27% overall (95% CI 22–32; I 2 =95·4%), 15% at 1 year (11–19; I 2 =91·6%), and 32% at 5 years (25–39; I 2 =94·3%). Overall mortality in patients with CPA with pulmonary tuberculosis as the predominant predisposing condition was 25% (16–35; I 2 =87·5%; 20 studies) and with chronic obstructive pulmonary disease was 35% (22–49; I 2 =89·7%; 14 studies). Mortality in cohorts of patients who underwent surgical resection was low at 3% (2–4). In the multivariable analysis, among predisposing respiratory conditions, pulmonary tuberculosis history had the lowest mortality hazard (relative to an absence of the disease at baseline), whereas worse outcomes were seen with underlying malignancy; subacute invasive pulmonary aspergillosis and chronic cavitary pulmonary aspergillosis subtypes of CPA were also significantly associated with increased mortality relative to simple aspergilloma on multivariable analysis. Mortality hazard increased by 25% with each decade of age (adjusted hazard ratio 1·25 [95% CI 1·14–1·36], p<0·0001). Interpretation CPA is associated with substantial mortality. Advancing age, CPA subtype, and underlying comorbidities are important predictors of mortality. Future studies should focus on identifying appropriate treatment strategies tailored to different risk groups. Funding None.
infectious diseases